The estimated Net Worth of Steve Forte is at least $145 Tisíc dollars as of 28 March 2024. Mr Forte owns over 1,614 units of Repare Therapeutics stock worth over $125,818 and over the last 4 years he sold RPTX stock worth over $19,015.
Mr has made over 3 trades of the Repare Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,614 units of RPTX stock worth $7,457 on 28 March 2024.
The largest trade he's ever made was buying 5,000 units of Repare Therapeutics stock on 23 June 2020 worth over $100,000. On average, Mr trades about 1,136 units every 172 days since 2020. As of 28 March 2024 he still owns at least 44,775 units of Repare Therapeutics stock.
You can see the complete history of Mr Forte stock trades at the bottom of the page.
Steve Forte is the Exec. VP & CFO at Repare Therapeutics.
Mr Forte is 42, he's been the Exec. VP & CFO of Repare Therapeutics since . There are 3 older and no younger executives at Repare Therapeutics. The oldest executive at Repare Therapeutics Inc. is Dr. Maria Koehler M.D., Ph.D., 64, who is the Exec. VP & Chief Medical Officer.
Steve's mailing address filed with the SEC is C/O REPARE THERAPEUTICS INC., , ST-LAURENT, A8, H4S 1Z9.
Over the last 4 years, insiders at Repare Therapeutics have traded over $111,956,457 worth of Repare Therapeutics stock and bought 8,747,790 units worth $117,182,784 . The most active insiders traders include Partners L P/Ilbiotechnolog..., David P Bonita a Group, Llc Green Jeremy Red.... On average, Repare Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $446,135. The most recent stock trade was executed by Lloyd Mitchell Segal on 28 March 2024, trading 5,141 units of RPTX stock currently worth $23,751.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
Repare Therapeutics executives and other stock owners filed with the SEC include: